Alexza Pharmaceuticals Inc (ALXA.O)
4.51USD
23 May 2013
$-0.16 (-3.43%)
$4.67
$4.59
$4.59
$4.41
617,372
393,741
$6.65
$2.55
ALXA.O
About
Overall
| Beta: | 1.74 |
| Market Cap (Mil.): | $71.24 |
| Shares Outstanding (Mil.): | 15.80 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| ALXA.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 51.10 | 35.42 |
| EPS (TTM): | -2.18 | -- | -- |
| ROI: | -157.67 | 1.74 | 18.86 |
| ROE: | -- | 2.98 | 19.73 |
Teva to market Alexza agitation treatment in the U.S
TEL AVIV - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Teva to market Alexza agitation treatment in the U.S.
TEL AVIV, May 8 - Teva Pharmaceutical Industries and Alexza Pharmaceuticals reached an exclusive U.S. license and supply agreement for Adasuve inhalation powder for the treatment of agitation associated with schizophrenia or bipolar I disorder in adults.
Alexza's agitation drug gets FDA approval
- Alexza Pharmaceuticals Inc said the U.S. health regulators approved Adasuve, making it the first treatment for schizophrenia and bipolar disorder that can be inhaled.
UPDATE 1-Alexza's agitation drug gets FDA approval
Dec 21 - Alexza Pharmaceuticals Inc said the U.S. health regulators approved Adasuve, making it the first treatment for schizophrenia and bipolar disorder that can be inhaled.
Alexza's agitation drug gets FDA approval
Dec 21 - Alexza Pharmaceuticals Inc said the U.S. health regulators approved Adasuve, making it the first treatment for schizophrenia and bipolar disorder that can be inhaled.
Alexza agitation drug gets EU recommendation, shares jump
- European health regulators recommended approval of Alexza Pharmaceuticals Inc's experimental drug Adasuve for controlling agitation in adults with schizophrenia and bipolar disorder, sending its shares up 19 percent.
UPDATE 2-Alexza agitation drug gets EU recommendation, shares jump
Dec 14 - European health regulators recommended approval of Alexza Pharmaceuticals Inc's experimental drug Adasuve for controlling agitation in adults with schizophrenia and bipolar disorders, sending its shares up 24 percent before the bell.
Competitors
| Price | Change | |
|---|---|---|
| Novartis AG (NOVN.VX) | CHF71.40 | -0.05 |
| Roche Holding Ltd. (ROG.VX) | CHF253.30 | +2.60 |
| Abbott Laboratories (ABT.N) | $37.48 | -0.24 |
| Bayer AG (BAYGn.DE) | €83.96 | +0.05 |
| Bayer AG (BAYE.F) | -- | -- |
| Eli Lilly & Co. (LLY.N) | $54.74 | -0.18 |
| Bristol Myers Squibb Co. (BMY.N) | $47.00 | +0.60 |
| Bristol Myers Squibb Co. (BMY_p.N) | $567.60 | 0.00 |
| Amgen, Inc. (AMGN.OQ) | $105.62 | +1.09 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
